Le Fur G, Imbault F, Mitrani N, Marquis F, Renault C, Dubroeucq M C, Gueremy C, Uzan A
Neuropharmacology. 1984 Feb;23(2A):169-73.
Two epimer quinoline derivatives, PK 5078 and PK 7059, have been shown to be potent at releasing 5-HT from blood platelets. Moreover PK 5078 was also a potent and selective inhibitor of the uptake of 5-HT, being about 20 times as active as clomipramine. Both drugs, like p-chloroamphetamine, released 5-HT but did not inhibit MAO-A. Whilst p-chloroamphetamine seemed to be active on the cytoplasmic pool of 5-HT and reserpine on the vesicular pool, PK 5078 and PK 7059 were effective first on the vesicular pool and then on the cytoplasmic pool. The quinoline derivatives were devoid of the typical side-effects of amphetamine-like drugs, i.e. hyperactivity, anorexia and group toxicity. For these reasons PK 5078 and PK 7059 can be considered to be a new type of selective 5.HT-releasing drug.
两种差向异构喹啉衍生物PK 5078和PK 7059已被证明在促使血小板释放5-羟色胺(5-HT)方面具有强效。此外,PK 5078还是一种强效且选择性的5-HT摄取抑制剂,其活性约为氯米帕明的20倍。这两种药物与对氯苯丙胺一样,能释放5-HT,但不抑制单胺氧化酶A(MAO-A)。虽然对氯苯丙胺似乎对5-HT的胞质池有作用,利血平对囊泡池有作用,但PK 5078和PK 7059首先对囊泡池有效,然后对胞质池有效。喹啉衍生物没有苯丙胺类药物的典型副作用,即多动、厌食和群体毒性。基于这些原因,PK 5078和PK 7059可被视为一种新型的选择性5-HT释放药物。